MESO

Mesoblast
MESO
Market cap $1.5B

11.78 USD

-0.38

3.13%

At close Jun 13, 4:00 PM EDT

After hours

11.98

+0.20

1.70%

1 day

-3.13%

5 days

0.34%

1 month

-1.09%

3 months

-11.30%

6 months

0.17%

Year to date

-42.84%

1 year

61.59%

5 years

-53.14%

10 years

-27.37%

About: Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Employees: 73

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

53% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 15

12% more funds holding

Funds holding: 60 [Q4 2024] → 67 (+7) [Q1 2025]

9% more call options, than puts

Call options by funds: $6.22M | Put options by funds: $5.69M

0.04% more ownership

Funds ownership: 0.26% [Q4 2024] → 0.3% (+0.04%) [Q1 2025]

20% less capital invested

Capital invested by funds: $59.9M [Q4 2024] → $48M (-$11.9M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MESO.

See Analyst Rankings

Financial journalist opinion

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

MESO's Off-the-shelf MSC/MPC platform treats severe inflammatory diseases without donor–recipient matching. This alleviates the typical need for immunosuppression. The FDA recently approved Ryoncil, which achieved as much as 70% response in pediatric SR-aGVHD patients. And it has adult SR-aGVHD and Crohn's Phase 3 trials underway. MESO's Revascor is also in trials for chronic low back pain and heart failure, and its accelerated BLA could position it as another revenue vertical in the next couple of.

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025.

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited.

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, to 104 million US lives insured by government and commercial payers.

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government's announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to the tariffs.

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

First Three Children to Commence Treatment With Ryoncil®

United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States.

Ryoncil® is Now Available for Purchase in the United States

See News Rankings

Charts implemented using Lightweight Charts™